• Molecular NameBentiromide
  • SynonymBentiromide [USAN:BAN:INN:JAN]; Bentiromido [INN-Spanish]; Bentiromidum [INN-Latin]; BTPABA; PFD; PFT
  • Weight404.422
  • Drugbank_IDDB00522
  • ACS_NO37106-97-1
  • Show 3D model
  • LogP (experiment)3.201
  • LogP (predicted, AB/LogP v2.0)3.09
  • pkaN/A
  • LogD (pH=7, predicted)0.31
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.77
  • LogSw (predicted, AB/LogsW2.0)0.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors4
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds7
  • TPSA115.73
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPrimarily hepatic. Enzymatic activity capable of hydrolyzing bentiromide has also been found in normal small intestine.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include shortness of breath and troubled breathing.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A